Revolution Medicines
NASDAQ · RVMD·Redwood City, CA·Mid-cap·Phase 3
Clinical-stage precision oncology company developing targeted therapies for RAS-addicted cancers. Lead asset daraxonrasib (RMC-6236), a multi-selective RAS(ON) inhibitor, is in Phase 3 trials for pancreatic and lung cancers. Pipeline also includes mutant-selective RAS(ON) inhibitors and RAS companion inhibitors.
Decks (2)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Revolution Medicines Corporate Presentation | Corporate overview | May 6, 2026 | 85 | |
| Revolution Medicines Corporate Presentation | Corporate overview | April 15, 2026 | 76 |